D
Dermaliq Therapeutics
Innovative dermatology solutions enhancing hair growth and wound healing with advanced topical therapies
About Dermaliq Therapeutics
Dermaliq Therapeutics is a pioneering company in the dermatology sector, focusing on the development of advanced topical therapies for hair growth and wound healing. The company serves a diverse clientele, including individuals seeking medical aesthetics, self-pay prescription products, and over-the-counter (OTC) solutions. Operating in the healthcare and pharmaceutical markets, Dermaliq leverages its unique hyliQ™ platform technology to deliver multiple active ingredients directly into the follicle and skin, enhancing efficacy and safety. The business model revolves around continuous clinical development and regulatory approval of its products, generating revenue through product sales and potentially licensing its technology. Dermaliq's flagship products, DLQ01 and DLQ03, have shown significant promise in clinical trials, demonstrating superior efficacy in hair regrowth and accelerated wound healing, respectively. The company is poised to become a leader in next-generation dermatological treatments, driven by a commitment to innovation and quality.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2022 | $15M | $60M | 3E Bioventures · Beijing Weiying Technology | ↗ |
Growth signals
Latest recorded traffic for Dermaliq Therapeutics is 1.8K monthly website visits, up 1025% over the last three months. Dermaliq Therapeutics's team declined 37.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Dermaliq Therapeutics in the Heidelberg ecosystem
The Dermaliq Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
3E Bioventures
Beijing Weiying Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Dermaliq Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Dermaliq Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









